You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Cardiovascular
NewAmsterdam Pharma Doses First Patient in Phase 2 Trial of Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
6 April 2022 - - Netherlands-based clinical-stage company NewAmsterdam Pharma has dosed the first patient in ROSE2, the company's Phase 2 trial of obicetrapib, a novel cholesteryl ester transfer protein inhibitor, the company said.
ROSE2 is a placebo-controlled, double-blind, randomized, Phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg in combination with ezetimibe 10 mg and as monotherapy, in each case as an adjunct to high-intensity statin therapy.
Ezetimibe is a cholesterol absorption inhibitor that works by partially blocking the absorption of cholesterol in the small intestine, causing the upregulation of low-density lipoprotein receptors - a mechanism of action that NewAmsterdam believes could be additive and potentially synergistic with CETP inhibition for reducing levels of low-density lipoprotein cholesterol (LDL-c).
Participants will be randomized to receive combination therapy (i.e., obicetrapib 10 mg + ezetimibe 10 mg), obicetrapib monotherapy (obicetrapib 10 mg), or placebo.
The primary objective of the ROSE2 trial is to evaluate the efficacy endpoint, which is the percent change from Day 1 to Day 84 in LDL-c for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group.
A total of 108 patients will be randomized to placebo, 10 mg obicetrapib monotherapy, or 10mg obicetrapib + 10mg ezetimibe combination therapy, dosed as a once-daily oral treatment for an 84-day treatment period.
Obicetrapib is a selective cholesteryl ester transfer protein inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events.
More than 100m people globally are not achieving LDL-c goals despite the current available standard of care.
Obicetrapib was previously tested in ROSE and TULIP1 randomized double-blind, placebo-controlled Phase 2 trials.
Results from the ROSE trial, presented in November 2021 at the AHA Scientific Sessions, demonstrated that patients on statin therapy who received 5 mg of obicetrapib saw an LDL-c reduction of 42%.
Patients who were part of the 10 mg cohort experienced a 51% reduction versus baseline, while the placebo cohort experienced a 7% reduction versus baseline.
Both doses were well tolerated, with no serious adverse effects in the two cohorts and two serious AEs in the placebo arm.
NewAmsterdam Pharma is a private clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where traditional therapies have been unsuccessful or are not tolerated.
NewAmsterdam is investigating obicetrapib, a next-generation cholesteryl ester transfer protein inhibitor, as the preferred LDL-c-lowering therapy for high-risk cardiovascular disease patients.
The company's ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) showed that obicetrapib 10mg reduced LDL-c by 51% versus baseline in patients on statin therapy (vs. a 7% reduction in the placebo arm).
Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, and closed a USD 196m (EUR 161m) series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital.
ROSE2 is a placebo-controlled, double-blind, randomized, Phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg in combination with ezetimibe 10 mg and as monotherapy, in each case as an adjunct to high-intensity statin therapy.
Ezetimibe is a cholesterol absorption inhibitor that works by partially blocking the absorption of cholesterol in the small intestine, causing the upregulation of low-density lipoprotein receptors - a mechanism of action that NewAmsterdam believes could be additive and potentially synergistic with CETP inhibition for reducing levels of low-density lipoprotein cholesterol (LDL-c).
Participants will be randomized to receive combination therapy (i.e., obicetrapib 10 mg + ezetimibe 10 mg), obicetrapib monotherapy (obicetrapib 10 mg), or placebo.
The primary objective of the ROSE2 trial is to evaluate the efficacy endpoint, which is the percent change from Day 1 to Day 84 in LDL-c for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group.
A total of 108 patients will be randomized to placebo, 10 mg obicetrapib monotherapy, or 10mg obicetrapib + 10mg ezetimibe combination therapy, dosed as a once-daily oral treatment for an 84-day treatment period.
Obicetrapib is a selective cholesteryl ester transfer protein inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events.
More than 100m people globally are not achieving LDL-c goals despite the current available standard of care.
Obicetrapib was previously tested in ROSE and TULIP1 randomized double-blind, placebo-controlled Phase 2 trials.
Results from the ROSE trial, presented in November 2021 at the AHA Scientific Sessions, demonstrated that patients on statin therapy who received 5 mg of obicetrapib saw an LDL-c reduction of 42%.
Patients who were part of the 10 mg cohort experienced a 51% reduction versus baseline, while the placebo cohort experienced a 7% reduction versus baseline.
Both doses were well tolerated, with no serious adverse effects in the two cohorts and two serious AEs in the placebo arm.
NewAmsterdam Pharma is a private clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where traditional therapies have been unsuccessful or are not tolerated.
NewAmsterdam is investigating obicetrapib, a next-generation cholesteryl ester transfer protein inhibitor, as the preferred LDL-c-lowering therapy for high-risk cardiovascular disease patients.
The company's ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) showed that obicetrapib 10mg reduced LDL-c by 51% versus baseline in patients on statin therapy (vs. a 7% reduction in the placebo arm).
Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, and closed a USD 196m (EUR 161m) series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital.
Login
Related Headlines
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal